These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 8418310)
1. Opportunities "opening up" for gene therapy. Vanchieri C J Natl Cancer Inst; 1993 Jan; 85(2):90-1. PubMed ID: 8418310 [No Abstract] [Full Text] [Related]
2. Combined zidovudine and interferon-alpha 2a therapy in children with acquired immune deficiency syndrome. Giovannini M; Zuccotti GV; Biasucci G; Locatelli V; Riva E J Int Med Res; 1992 Jun; 20(3):295-301. PubMed ID: 1397675 [TBL] [Abstract][Full Text] [Related]
16. [Treatment of 5 patients affected by Kaposi's sarcoma and AIDS with recombinant interferon alfa-2A (roferon-A)]. Lopez Bran E; Aguilar R; Marron JA; Figueredo MA; Garcia Ruiz JM Med Cutan Ibero Lat Am; 1989; 17(4):269-73. PubMed ID: 2693866 [TBL] [Abstract][Full Text] [Related]
17. Scientists changing therapy outlook for AIDS patients. Antoine FS J Natl Cancer Inst; 1990 Jun; 82(12):992-6. PubMed ID: 2348475 [No Abstract] [Full Text] [Related]
18. The clinical applications of colony-stimulating factors in acquired immunodeficiency syndrome. Scadden DT Semin Hematol; 1992 Oct; 29(4 Suppl 3):33-7. PubMed ID: 1492232 [No Abstract] [Full Text] [Related]
19. Recombinant alpha-2a interferon treatment in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC): clinical and immunological evaluation. Mezzaroma I; Avella A; Paganelli R; Ensoli B; d'Offizi G; Sirianni MC; Luzi G; Valdarchi C; Aiuti F Allergol Immunopathol (Madr); 1991; 19(5):201-7. PubMed ID: 1811417 [TBL] [Abstract][Full Text] [Related]
20. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Daar ES; Li XL; Moudgil T; Ho DD Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6574-8. PubMed ID: 2395859 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]